BioSpace

Syndax ends fibrosis program for Niktimvo after mid-stage disappointment

Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.

By BioSpace

1 min read
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights